These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22023452)

  • 1. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E; Garcia-Manero G; Taher A; Kantarjian HM
    Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineating parameters of iron overload in MDS patients treated with deferasirox.
    Leitch HA
    Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
    [No Abstract]   [Full Text] [Related]  

  • 12. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
    Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
    Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
    Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
    Gattermann N; Finelli C; Della Porta M; Fenaux P; Stadler M; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Marcellari A; Roubert B; Rose C
    Haematologica; 2012 Sep; 97(9):1364-71. PubMed ID: 22419577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.